Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 03 April 2017 | By Michael Mezher
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) last week adopted an updated guideline on clinical development for fixed combination drugs, which is expected to take effect in October.
Specifically, the guideline discusses the evidence needed to support the authorization of drugs containing two or more active substances in a single pharmaceutical, and applies to fixed combination drugs consisting of authorized and new active substances.
EMA says the guideline, while focusing on small molecule drugs, is applicable to biologics as well.
In general, EMA says that sponsors must show data to support the pharmacological and medical rationale for the combination.
To do so, sponsors must establish the evidence base for the contribution of all active substances included in the combination to the desired therapeutic effect and demonstrate a positive benefit-risk balance for the combination.
According to a 2013 concept paper, the 2009 revision needed to be updated to clarify questions on the legal basis for approving fixed combination products, as the earlier version incorrectly suggested that Article 10(b) of Directive 2001/83/EC is the sole legal basis for authorizing FDCs.
Now, EMA says: "The choice of legal basis lies with the applicant. In every case, the application must comply with the dossier requirements as set out in Directive 2001/83/EC and its Annex I."
EMA also says the new revision removes discussion of "combination packs," as the agency says it "is no longer considered appropriate to address … within the scope of this guideline."
In the previous version, EMA said the "scientific principles applicable to fixed combination products will also be applied in the assessment of 'combination pack' medicinal products."
Guideline
Regulatory Focus newsletters
All the biggest regulatory news and happenings.